NasdaqGS:MRNABiotechs
Why Moderna (MRNA) Is Up 7.8% After FDA Clears First mRNA Flu Shot for Older Adults
Earlier this month, Health Canada authorized Moderna to begin a Phase I clinical trial of its mRNA Bundibugyo Ebola vaccine candidate, while the U.S. FDA recently approved mFlusiva as the first mRNA flu vaccine for adults aged 50 and older, including accelerated approval for those 65 and above.
This pairing of an early-stage Ebola program with full U.S. approval for an mRNA flu shot highlights how Moderna is extending its mRNA platform beyond COVID-19 into both seasonal and outbreak-driven...